Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.
about
Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasmsC-->U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzymeLeukemia-associated, constitutively active mutants of SHP2 protein tyrosine phosphatase inhibit NF1 transcriptional activation by the interferon consensus sequence binding proteinMouse models of neurofibromatosis 1 and 2.Eliminating barriers to personalized medicine: learning from neurofibromatosis type 1Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantationA RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressorReconciling diverse mammalian pigmentation patterns with a fundamental mathematical modelMxi1 mutations in human neurofibrosarcomasFetal antigen 1, a member of the epidermal growth factor superfamily, in neurofibromas and serum from patients with neurofibromatosis type 1RAS diseases in childrenPAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signalingNeurofibromatosis type 1 - a model for nervous system tumour formation?PU.1, interferon regulatory factor (IRF) 2, and the interferon consensus sequence-binding protein (ICSBP/IRF8) cooperate to activate NF1 transcription in differentiating myeloid cellsThe interferon consensus sequence-binding protein activates transcription of the gene encoding neurofibromin 1Germline KRAS mutations cause Noonan syndromeLoss of the nf1 tumor suppressor gene decreases fas antigen expression in myeloid cellsAblation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brainNeurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytesThe neurofibromatosis type 1 (Nf1) tumor suppressor is a modifier of carcinogen-induced pigmentation and papilloma formation in C57BL/6 miceGenetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivoOncogenic Kras expression in postmitotic neurons leads to S100A8-S100A9 protein overexpression and gliosisHyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitroGenome-wide analysis reveals adaptation to high altitudes in Tibetan sheepCotargeting MNK and MEK kinases induces the regression of NF1-mutant cancersRas dependent paracrine secretion of osteopontin by Nf1+/- osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model.Optimizing biologically targeted clinical trials for neurofibromatosis.Genetic predispositions and childhood cancer.Ral is both necessary and sufficient for the inhibition of myeloid differentiation mediated by RasNf1 Haploinsufficiency Alters Myeloid Lineage Commitment and Function, Leading to Deranged Skeletal Homeostasis.Dual loss of rb1 and Trp53 in the adrenal medulla leads to spontaneous pheochromocytoma.Myelodysplasia and myeloproliferative disorders in childhood: an update.Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity.The NF1 tumor suppressor critically regulates TSC2 and mTOR.Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein.Two distinct interleukin-3-mediated signal pathways, Ras-NFIL3 (E4BP4) and Bcl-xL, regulate the survival of murine pro-B lymphocytes.Response and resistance to MEK inhibition in leukaemias initiated by hyperactive RasMast cells and the neurofibroma microenvironmentNF1 inactivation in adult acute myelogenous leukemiaRas in cancer and developmental diseases
P2860
Q24530021-DE00CB69-B2E9-41DF-8B3F-1CB42F1057B4Q24633130-2FE10E59-FA0D-40A2-9F11-CB2BA1895A14Q24670487-9A3854F5-F92D-4D16-A245-D96C96AFF61AQ24682869-340AD1F1-160C-4EF4-9EFE-5F2E4A0D114AQ26828988-B840B46F-F802-4878-9BD5-942C41BA396DQ26851000-382EFDEB-034E-4793-8200-05885D8F7D82Q27003534-5F70533F-8E9E-4ADE-BE98-2ACB32D39C3FQ27335853-9EA4F4C6-B8BB-46BD-95F2-09D90B326DA9Q28143525-3623C82A-3733-4F34-97FF-55083F3B1AA4Q28198026-237EC884-E4F1-47FA-AEBE-8FEAA073A6C5Q28252058-EF5562EE-89A9-480E-8D35-9FF294E0F421Q28253621-F11E3BD0-415A-4AF6-9103-BE69187277ACQ28265284-72A040EF-BAAD-44C6-888C-EAF12D72BA45Q28281520-19FD65DB-90ED-474C-BDAC-A82D64F38143Q28282456-3154F222-799C-48C4-9120-592FA4AEFD6EQ28297024-C964B6A0-6B38-49F5-9AF0-534679B66469Q28504730-E6104C9E-81AC-4B18-83F3-4DC815545931Q28506943-36366C9F-51EA-4FA7-89EA-71A26FAB97BEQ28506980-4FD70ADB-FEEF-4D17-82D0-50BB996E084BQ28511045-4C9DCF03-6377-4FED-841A-2A9249C9900AQ28585229-C7D0ED2A-0E92-4967-8C72-5EFA64728EF5Q28589373-ECB6D8EB-6521-4787-A768-D4CD4AD1B577Q28594862-7B52C97B-74A7-45B3-AFAB-34042D83DB88Q28602124-F495B730-2E0A-4198-84AB-ADAACD3001A0Q28829666-773A02BC-3818-4FE8-A62E-51BEDD0863EDQ30375214-51580718-75F0-40AA-8810-22D2E2C21B19Q30438898-A1033D88-AC59-47CE-8AE7-380F32B94077Q30499276-3A7EAA29-DE14-4916-BE41-4CD6D8994711Q33241589-75FE3E21-54E2-4379-9CC5-C303E9590EDCQ33718764-AEA8F2BD-03EE-49B2-BF5E-C0AD6258B2FAQ33727037-A3493DCF-F417-4F67-A764-FB3BF7BC7620Q33770597-8D5BE49D-6516-4CFD-B41C-DAAE7263CBECQ33831164-DED9E168-C0C1-4406-98F7-D582D725D792Q33841600-D973E859-70C7-4A61-8529-F8B82B549B61Q33884193-BAFAAB8A-C1FC-4F1A-9E63-21AC8E84EF66Q33957711-8E60D39F-5BC4-402C-BE5D-4AE590685C24Q33993387-645F2CF0-718E-4752-B46E-53E9483638B0Q34022409-F0742B30-8C2C-4F70-AA66-8BED803B73EDQ34065032-1EAEDDE5-10BF-46BB-BA64-CEB0559FE01EQ34202697-7FE434C9-460A-4379-9C42-4E3A5AC40ED0
P2860
Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Loss of NF1 results in activat ...... rowth in haematopoietic cells.
@en
Loss of NF1 results in activat ...... rowth in haematopoietic cells.
@nl
type
label
Loss of NF1 results in activat ...... rowth in haematopoietic cells.
@en
Loss of NF1 results in activat ...... rowth in haematopoietic cells.
@nl
prefLabel
Loss of NF1 results in activat ...... rowth in haematopoietic cells.
@en
Loss of NF1 results in activat ...... rowth in haematopoietic cells.
@nl
P2093
P2860
P356
P1433
P1476
Loss of NF1 results in activat ...... rowth in haematopoietic cells.
@en
P2093
Freedman MH
McCormick F
Thompson P
P2860
P2888
P304
P356
10.1038/NG0296-144
P407
P577
1996-02-01T00:00:00Z